Literature DB >> 11992410

Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients.

Yoshiaki Maeda1, Masaaki Ito, Nanae Harashima, Tetsuya Nakatsura, Naoya Hida, Nobue Imai, Yuuji Sato, Shigeki Shichijo, Satoru Todo, Kyogo Itoh.   

Abstract

To identify CTL-directed antigens in gastrointestinal cancer, we have investigated antigens recognized by the HLA-A2-restricted CTL line established from T cells infiltrating into colon cancer and report herein cleavage and polyadenylation specificity factor (CPSF) as a potent antigen holding peptides capable of inducing CTLs. Five peptides at amino acid positions 250-258, 392-400, 534-542, 1296-1304 and 1359-1368 of CPSF, which were recognized by the CTL line, were found to have the ability to induce HLA-A2-restricted and tumor-specific CTLs in peripheral blood mononuclear cells of the majority (69%, 11/16) of gastrointestinal cancer patients with different HLA-A2 subtypes. Thus, these peptides might be appropriate molecules for use in the peptide-based specific immunotherapy of HLA-A2(+) patients with gastrointestinal cancers. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992410     DOI: 10.1002/ijc.10377

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Personalized ex vivo multiple peptide enrichment and detection of T cells reactive to multiple tumor-associated antigens in prostate cancer patients.

Authors:  Pavla Taborska; Dmitry Stakheev; Zuzana Strizova; Katerina Vavrova; Michal Podrazil; Jirina Bartunkova; Daniel Smrz
Journal:  Med Oncol       Date:  2017-09-02       Impact factor: 3.064

Review 2.  Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.

Authors:  Neftali Ortega Alarcon; Maddy Jaramillo; Heidi M Mansour; Bo Sun
Journal:  Pharmaceutics       Date:  2022-07-11       Impact factor: 6.525

3.  Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma.

Authors:  K Yoshimura; T Minami; M Nozawa; H Uemura
Journal:  Br J Cancer       Date:  2013-03-07       Impact factor: 7.640

4.  Heat shock cognate protein 70 encodes antigenic epitopes recognised by HLA-B4601-restricted cytotoxic T lymphocytes from cancer patients.

Authors:  K Azuma; S Shichijo; H Takedatsu; N Komatsu; H Sawamizu; K Itoh
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.